2nd IAS Conference on HIV and Pathogenesis



Medical Advocates for Social Justice
Conference Highlights: Select Conference News. Abstracts and Posters from the

		2nd IAS Conference on HIV and Pathogenesis Paris, France July 14-17, 2003

Main New/Newsworthy Conference Updates: Main Page Home

Last Update: December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader 5 .

Conference Report

FULL-TEXT PDF ARTICLE
Key Clinical Studies at the 2nd IAS Conference on HIV Pathogenesis and Treatment*
Mascolini, M
Report

Resource Limited Countries ARV Access

PDF POSTER
Association Driven Care and Treatment (ADCT): A Model for HIV/AIDS in Resource Limited Settings
E Baramperave, Z Bureima, A. Herman, et al.
Poster

PDF POSTER
AIDS Empowerment and Treatment International (AIDSETI) Network: Expanding Access to AIDS Treatment in Africa and the Caribbean
F Ndayishimiye, MJ Mbuzenakamwe, E Ouerraoga, et al.
Poster

HIV Pregnancy/Neonates

PDF POSTER
Live births of HIV+ mothers. Are they different from others? A study from Rio de Janeiro City, Brazil, 1999 – 2001.
Saraceni V, Rapparini C, Cruz M, et al.
Poster

PDF POSTER
The Odessa Model: A Case Study of the Development of a Replicable Prototype for the Reorganization of a Maternal Outreach and Delivery System for HIV-infected Pregnant Women in Resource-limited Countries of the Former Soviet Union
S. Posokhova, N. Nizova, et al.
Poster

Multicentre, Randomized Controlled Trial, Assessing the Safety and Efficacy of Nevirapine
in Addition to Zidovudine for the Prevention of Perinatal HIV In Thailand: PHPT-2 Update
M Lallemant, G Jourdain, S Le Coeur, et al.
Abstract

Effectiveness of a Short Course of Zidovudine + Lamivudine and Peripartum Nevirapine
to Prevent HIV-1 Mother-to-Child Transmission
F Dabis, DK Ekouévi, F Rouet, et al
Abstract

Reducing Risk of HIV-1 Transmission from Mother to Infant Through Breastfeeding Using Antiretroviral Prophylaxis in Infants
J Vyankandondera, S Luchters. E Hassink, et al
Abstract

Mortality Among HIV-Infected Mothers and Children's Feeding Modality: The Breastfeeding and
HIV International Transmission Study (BHITS)
ML Newell, J Read, V Leroy, F Dabis
Abstract

Mortality in Breast-Fed and Formula-Fed Children Born to HIV-Infected Women
in a PMTCT Project in Abidjan (Côte d'Ivoire): Ditrame Plus ANRS 1202
R Becquet, L Becquet, DK Ekouevi, et al
Abstract

Drug Data

Atazanavir

POWER-POINT PRESENTATION
Body Fat Effects of Atazanavir (ATV) and Efavirenz (EFV) Each Combined With Fixed-Dose Zidovudine (ZDV) and Lamivudine (3TC) 48-Week Results From the Metabolic Substudy of BMS-034
JG Jemsek, E Arathoon, M Arlotti, et al
Poster Abstract

PDF POSTER
Characterization of the Steady-State Pharmacokinetic (PK) Profile of Atazanavir (ATV) beyond the 24-hour Dosing Interval
S Agarwala, D Grasela, M Child, et al
Poster

POWER-POINT PRESENTATION
Atazanavir (ATV) With Ritonavir (RTV) or Saquinavir (SQV) vs Lopinavir/Ritonavir (LPV/RTV) in Patients With Multiple Virologic Failures: 24-Week Results From BMS AI424-045
R Badaro, E DeJesus, A Lazzarin, et al.
Presentation

Regimen Containing Ritonavir-Boosted REYATAZ (atazanavir sulfate) Demonstrates Comparable Viral Load Reduction Through Week 24 to a Regimen Containing Kaletra (lopinavir/ritonavir) in Highly-Treatment Experienced HIV/AIDS Patients
News Release

Emtricitabine

Once Daily Emtricitabine Compared to Twice Daily Abacavir within a HAART Regimen in Antiretroviral Drug-Naive HIV-1 Infected Patients (ODECTA)
AL Shaw, G Shen, CW Wakeford , et al
News Release

Phase III Trial of Emtriva, New Once-Daily Capsule for HIV, Shows Continued Response through 60 Weeks
News Release

A Randomized, Double-Blind, Multicenter Comparison of Emtricitabine QD to Stavudine BID in Treatment-Naïve HIV-Infected Patients
F Raffi, M Saag, P. Cahn, et al,
Abstract

Efficacy of Emtricitabine (FTC) in HIV-Infected Patients with High-Pretreatment Viral Load
I Sanne, M Saag, A Shaw, et al
Abstract

Efavirenz

Durability of efavirenz compared to nevirapine with long term follow-up of an antiretroviral naïve cohort
Matthews GV, Mandalia S, Orkin C, et al.
Poster

Ambulatory EEG and Therapeutic Drug Monitoring in the Management of Efavirenz-Related Insomnia
P Barreiro, L Gallego, R del Río et al
Abstract

Enfuvirtide

Enfuvirtide TORO Studies: 48 Week Results Confirm 24 Week Findings
Katlama C, Arastéh K, Clotet B, et al
Abstract

Analysis of Virological Response of Enfuvirtide in TORO: Implications for Patient Management
Montaner J, DeMasi R, Delehanty J, et al
Abstract

New Data Show FUZEON-Based Regimens Deliver Superior, Sustained Response in Treatment-Experienced Patients
News Release

Lopinavir

PDF POSTER
Steady-State Pharmacokinetics and Short-Term Virologic Response of Two Lopinavir/ritonavir (LPV/r) High-Dose Regimens in Multiple Antiretroviral-Experienced Subjects (Study 049)
C Flexner,Y-L Chiu, C Foit, et al.
Poster
PDF POSTER
CD4 Cell Increases Through More Than 4 Years in Antiretroviral-Naïve HIV+ Patients Treated with Lopinavir/ritonavir-Based Therapy
H Kessler, M Heath-Chiozzi, M King, et al.
Poster

PDF POSTER
SOKRATES: Prospective Evaluation of Resistance in Protease During Lopinavir/ritonavir Treatment
B daSilva, P Cernohous, M King, et al
Poster

PDF POSTER
Virological and Pharmacological Parameters Predicting the Response to Lopinavir/ritonavir AG Marcelin, I Cohen-Codar, M King, et al
Poster

PDF POSTER
Relationship Between Adherence and the Development of Viral Resistance in Antiretroviral-Naive Patients Treated with Lopinavir/ritonavir (LPV/r) or Nelfinavir (NFV)
M King, S Brun, J Tschampa, et al
Poster

Interleukin-7 Levels Predict Treatment Response in Advanced HIV-Infected Subjects Receiving Lopinavir/Ritonavir Therapy
JP Routy, GHR Smith, N Gilmore, et al
Abstract

Assessment of Depression in Patients after Substitution of their PI/NNRTI with Lopinavir/Ritonavir (LPV/r)
J Rockstroh, Y Shen, R Bortolozzi, et al.
Abstract

Salvage Therapy with Lopinavir/Ritonavir (LPV/R), Amprenavir (APV) ± an Additional Boost with Ritonavir (RTV): 1-Year Results of Puzzle 1-ANRS104 Study
G Raguin, G Chene L Morand-Joubert, et al
Abstract

The LOPSAQ Study: 24 Week Analysis of the Double Protease Inhibitor (PI) Salvage Therapy Regimen Containing Lopinavir (LPV/r) plus Saquinavir (SQV) without any additional Antiretroviral (ART) Therapy
S Staszewski, B Dauer, N Von Hentig, et al
Abstract

HIV Patients Experiencing Moderate Side Effects Reported Improved Outcomes when
Changed to a Regimen Containing Kaletra
News Release

Nelfinavir

Study Presented by Agouron/Pfizer Indicates Improved Diarrhea Management for Viracept
News Release

Nevirapine

PDF POSTER
Systemic Review of Nevirapine Versus Efavirenz-Containing Three-Drug Regimens for Initial Treatment of HIV Infection
Neuwelt MD, Bacon O, Kennedy G, Rutherford GW
Poster Abstract
The pdf poster is a large file and may take a few minutes to download

Long-Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV Patients with Undetectable Viral Load
Gil P, Górgolas M, Estrada V, et al.
Abstract

Multicentre, Randomized Controlled Trial, Assessing the Safety and Efficacy of Nevirapine in Addition to Zidovudine for the Prevention of Perinatal HIV In Thailand:
PHPT-2 Update
M Lallemant, G Jourdain, S Le Coeur, et al.
Abstract

Patients Switching to VIRAMUNE from a PI-based Regimen Maintain Viral Suppression and
Demonstrate Improved Triglyceride and Cholesterol Levels
News Release

Meta-Analysis of Six Completed Studies with a Total of 3,205 Patients
News Release

Saquinavir

PDF POSTER
Saquinavir 500 mg Tablet, A New Formulation, Has Similar Bioavailability to Invirase 200 mg Capsule for Healthy Volunteers at 1000/100 MG BID Dosing with Ritonavir
Y Hijazi, M Riek, E Gaudeu-Ehrhart, S Grange
Poster

Investigation Formulation of Saquinavir Could Simplify Dosing Regimens
News Release

Tenofovir

Characterization of Virologic Failure through 96 Weeks among Treatment-Naive Patients Taking Tenofovir DC (TDF) or Stavudine in Combination with Lamivudine (3TC) and Efavirenz (EFV)
MD Miller, NA Margot, DJ McColl, et al
Abstract

Similar 96-Week Efficacy Profile Regardless of Baseline Variable for Tenofovir Disoproxil Fumarate (TDF) versus Stavudine (d4T) when Used in Combination with Lamivudine and Efavirenz in Antiretroviral Naive Patients
AL Pozniak, JE Gallant, S Staszewski, et al
Abstract

Tipranavir

The Inhibitory Quotient (IQ) of Tipranavir/Ritonovir (TPV/r) in Triple Class Experienced
HIV + Patients; Results from BI 1182.52
DL Mayers, VM Kohlbrenner, C Dohnanyi, et al.
Abstract

Tipranavir/Ritonavir/(TPV/r) Demonstrates a Robust Resistance Profile in Multiple Protease In-Experienced Patients Correlation of Baseline Genotype and Antiviral Activity in BI 1182.52.
K Squires, S McCallister, A Lazzarin , et al. Abstract

Standard Does of Efavirenz (EFV), Zidovudine (ZDV), Tenofovir (TDF), and Didanosine (ddI) May Be Given with Tipranavir/Ritonavir (TPV/r).
PJ Roszko, K Curry, B Brazina, et al
Abstract

Zidovudine

Effectiveness of a Short Course of Zidovudine + Lamivudine and Peripartum Nevirapine
to Prevent HIV-1 Mother-to-Child Transmission
F Dabis, DK Ekouévi, F Rouet, et al
Abstract

Multicentre, Randomized Controlled Trial, Assessing the Safety and Efficacy of Nevirapine in Addition to Zidovudine for the Prevention of Perinatal HIV In Thailand:
PHPT-2 Update
M Lallemant, G Jourdain, S Le Coeur, et al.
Abstract

640385 (VX-385)

Resistance Data Presented on GlaxoSmithKline and Vertex's Investigational Protease
Inhibitor, 43390
News Release

Investigational HIV Protease Inhibitor 640385 (VX-385) Combats Resistance: Preclinical results presented at 2nd IAS Conference on HIV Pathogenesis and Treatment
News Release

Therapeutic Drug Monitoring

ViroLogic Announces Study Supporting Use of Replication Capacity As a Predictor of
Clinical Progression to AIDS
News Release

Post-Exposure Prophylaxis

Highly Targeted Use of Non-Occupational Use of Non-Occupational Prophylaxis (NPEP) in Australia
A Grulich, W Zheng, S Kippax , DE Smith
Abstract

Main New/Newsworthy Conference Updates: Main Page Home

2nd IAS Conference on HIV and Pathogenesis
A Medical Advocates for Social Justice Update

*© 2001, IAS, All rights reserved.

Material on the IAS site IAS maintains this server to enhance public access to information about its activities. All information and content on the site, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.